Related Experiment Video
Updated: Jan 26, 2026
05:36
Author Spotlight: Advancing Gene Silencing Research in Silkworms with dsRNA Delivery Through Feeding Chitosan Nanoparticles
Published on: October 4, 2024
2.6K
Chitosan-Modified PLGA Nanoparticles for Control-Released Drug Delivery
Boting Lu1, Xikun Lv2, Yuan Le3
1State Key Laboratory of Organic-Inorganic Composites, Beijing University of Chemical Technology, Beijing 100029, China. 2016200044@mail.buct.edu.cn.
Polymers
|April 10, 2019
Summary
Chitosan-modified poly (lactic-co-glycolic acid) nanoparticles (PLGA NPs) offer improved drug delivery. These modified nanoparticles show sustained release and enhanced anticancer drug toxicity, making them promising for cancer therapy.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Drug Delivery Systems
Background:
- Poly (lactic-co-glycolic acid) nanoparticles (PLGA NPs) are biocompatible and biodegradable drug carriers.
- A key limitation of PLGA NPs is the burst release of encapsulated drugs.
- Chitosan (CS) modification can potentially improve nanoparticle properties and drug release profiles.
Purpose of the Study:
- To prepare and characterize chitosan-modified PLGA nanoparticles (CS-PLGA NPs).
- To evaluate the drug release kinetics and cellular uptake of CS-PLGA NPs.
- To assess the potential of CS-PLGA NPs as anticancer drug carriers.
Main Methods:
- CS-PLGA nanoparticles were synthesized using a high-gravity rotating packed bed (RPB) technique.
- Particle size, zeta potential, and drug encapsulation efficiency were analyzed.
- In vitro drug release studies were conducted at different pH values (5.5 and 7.4).
- Cellular uptake and viability assays were performed.
Main Results:
- CS modification increased particle size, zeta potential, and drug encapsulation efficiency of PLGA NPs.
- CS-PLGA NPs exhibited reduced initial burst release and sustained drug release compared to unmodified PLGA NPs.
- Drug release was faster at acidic pH (5.5) than neutral pH (7.4).
- Cellular uptake of CS-PLGA NPs was enhanced, leading to reduced cell viability.
Conclusions:
- CS-modified PLGA NPs demonstrate sustained drug release and improved anticancer efficacy.
- These nanoparticles show potential as effective carriers for anticancer drugs.
- The RPB method offers an efficient way to produce CS-modified PLGA NPs.
Related Concept Videos
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.6K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.6K
01:16Drug Delivery: Overview
803
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
803
01:19Antiasthma Drugs: Leukotriene Modifiers
1.8K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.8K
01:18Drug Delivery: Enteral Route
1.7K
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
1.7K
01:29Drug Delivery: Parenteral Route
1.6K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
1.6K
01:22Drug Delivery: Miscellaneous Routes
758
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
758